ArticleNPJ breast cancer2025

A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.

Jessica Mezzanotte-Sharpe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.